Pollyea Daniel A
University of Colorado School of Medicine, Division of Hematology, Aurora, CO 80045.
Clin Lymphoma Myeloma Leuk. 2020 Sep;20 Suppl 1:S25-S26. doi: 10.1016/S2152-2650(20)30450-X.
The developmental path for venetoclax in acute myeloid leukemia (AML) has been rapid and stands in stark contrast to the incremental progress that has characterized the field in previous decades. For perspective, on December 31, 2013, the first AML patient was enrolled into a study using venetoclax; 59 months later, on November 21, 2018, venetoclax received accelerated approval by the FDA for use in AML. In June 2020, Dr. DiNardo presented the results of the required confirmatory study at the European Hematology Association meeting, showing that venetoclax with azacitidine resulted in a superior response rate and overall survival compared to azacitidine alone for older, newly diagnosed AML patients. This swift progress has provided a welcome and potent new therapy for patients with AML; with it come questions about how its role can be expanded, and how its use can be optimized.
维奈克拉在急性髓系白血病（AML）中的发展历程迅速，与该领域过去几十年渐进式的进展形成鲜明对比。从时间线来看，2013年12月31日，首例AML患者被纳入使用维奈克拉的研究；59个月后的2018年11月21日，维奈克拉获得美国食品药品监督管理局（FDA）的加速批准，用于治疗AML。2020年6月，迪纳尔多博士在欧洲血液学协会会议上公布了所需的验证性研究结果，表明对于新诊断的老年AML患者，维奈克拉联合阿扎胞苷的缓解率和总生存率优于单独使用阿扎胞苷。这一迅速进展为AML患者提供了一种受欢迎且有效的新疗法；随之而来的问题是，如何扩大其作用，以及如何优化其使用。
